Profile: Allakos Inc (ALLK.OQ)

ALLK.OQ on NASDAQ Stock Exchange Global Select Market

10:56pm IST
Change (% chg)

$0.69 (+0.78%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Allakos, Inc. incorporated on March 9, 2012, is a clinical-stage biotechnology company. The Company is focused on providing treatments by developing monoclonal antibodies that selectively target mast cells and eosinophils related diseases. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage.

The Company is testing AK002 in a double-blind, placebo-controlled Phase 2 trial in patients, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.

Company Address

Allakos Inc

975 Island Dr Ste 201
REDWOOD CITY   CA   94065-5173
P: +1650.5975002
F: +1302.6555049

Company Web Links